Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price & Analysis
Arrowhead Pharmaceuticals, Inc. (ARWR) rose 0.15% to USD 74.52 as of June 13, 2026 at 11:45 UTC, according to Nexqual real-time market data.
ARWR last closed at USD 74.41; the session ranged USD 73.29–75.45 on volume of 1,166,620 shares. Market capitalization is $10.50B, with a 52-week range of USD 14.3–82.26 (NMS). Source: Nexqual, June 13, 2026 at 11:45 UTC.
Key Statistics (as of June 13, 2026 at 11:45 UTC)
| Price | USD 74.52 |
|---|---|
| Change | ▲ 0.15% (up) |
| Previous Close | USD 74.41 |
| Open | USD 74.53 |
| Day Range | USD 73.29 – 75.45 |
| 52-Week Range | USD 14.3 – 82.26 |
| Volume | 1,166,620 shares |
| Market Cap | $10.50B |
| Exchange | NMS |
Technical Analysis (ARWR)
Nexqual's technical model rates ARWR "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 13, 2026 at 11:45 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.39 (neutral) |
| vs SMA50 | Above (USD 72.76) |
| MACD | -0.04 (negative) |
Analyst Ratings (ARWR)
Wall Street analysts rate ARWR "Buy" based on 12 analysts, with a mean price target of USD 88.17 (range USD 46–110), per Nexqual as of June 13, 2026 at 11:45 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 88.17 |
| High Target | USD 110 |
| Low Target | USD 46 |
| Buy / Hold / Sell | 11 / 2 / 0 |
Earnings (ARWR)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -1.2 |
| Revenue Estimate | $46.67M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.93 vs est -1.11 ▲ beat |
| 2025-12-31 | USD 0.22 vs est -0.37 ▲ beat |
| 2025-09-30 | USD -0.18 vs est -0.16 ▼ miss |
| 2025-06-30 | USD -1.26 vs est -1.1 ▼ miss |
Source: Nexqual, June 13, 2026 at 11:45 UTC.
Financials & Fundamentals (ARWR)
| Total Revenue | $622.01M |
|---|---|
| Revenue Growth (YoY) | -86.40% |
| Gross Margin | +100.00% |
| Operating Margin | -191.57% |
| Profit Margin | -48.38% |
| ROE | -42.37% |
| Debt / Equity | 231.05 |
| Current Ratio | 6.23 |
| Total Cash | $1.78B |
| Total Debt | $1.38B |
| Free Cash Flow | $-46.12M |
Source: Nexqual, June 13, 2026 at 11:45 UTC.
Financial Health Score (ARWR)
Nexqual rates Arrowhead Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 13, 2026 at 11:45 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $1.78B cash vs $1.38B debt, net cash position |
| Cash Flow | Weak — FCF negative: -$46M, burning cash |
| Efficiency | Critical — ROE -42%, ROA -7.2% |
Ownership (ARWR)
| Insider Ownership | +3.67% |
|---|---|
| Institutional Ownership | +88.55% |
| Shares Outstanding | 140.86M |
| Float | 122.78M |
| Short % of Float | +12.25% |
Source: Nexqual, June 13, 2026 at 11:45 UTC.
Leadership (ARWR)
Arrowhead Pharmaceuticals, Inc. is led by Christopher R. Anzalone (age 56), Chairman, CEO & President, per Nexqual as of June 13, 2026 at 11:45 UTC.
| Chairman, CEO & President | Christopher R. Anzalone (age 56) |
|---|---|
| Chief Financial Officer | Daniel J. Apel (age 59) |
| COO & Secretary | Patrick O'Brien J.D., PharmD (age 61) |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | Mark M. Davis |
| Chief Scientific Officer | Tao Pei |
Major Backers & Investors (ARWR)
Notable institutional backers of Arrowhead Pharmaceuticals, Inc. include Avoro Capital Advisors LLC, FMR, LLC, Invesco, according to Nexqual as of June 13, 2026 at 11:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Avoro Capital Advisors LLC | 7.6% |
| FMR, LLC | 5.16% |
| Invesco | 3.41% |
| Fidelity | 2.53% |
| Fred Alger Management, LLC | 2.37% |
| Vestal Point Capital, LP | 1.62% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.51% |
| Vanguard Group | 16.86% |
| State Street | 5.77% |
| Geode Capital | 3.04% |
Source: Nexqual, June 13, 2026 at 11:45 UTC.
From Arrowhead Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2025-11-25)
Key Strengths & Strategy (as disclosed to the SEC)
- The Company's broad portfolio of RNA trigger structures and chemistries, including certain proprietary structures, enable the Company to optimize each drug candidate on a target-by-target basis and utilize the combination of structure and chemical modifications that yield the most potent RNAi therapeutic candidate.
- Under the assigned Alnylam-Novartis License, the Company acquired a worldwide, royalty-bearing, exclusive license with limited sublicensing rights to existing and future Alnylam intellectual property (including intellectual property that came under Alnylam's control on or before March 31, 2016), excluding intellectual property concerning delivery technology, to research, develop and commercialize 30 undisclosed gene targets.
- Pursuant to this acquisition, Roche assigned to the Company its entire rights under certain licenses including: the License and Collaboration Agreement between Roche and Alnylam dated July 8, 2007; the Non-Exclusive Patent License Agreement between Roche and MDRNA, Inc. dated February 12, 2009 ("MDRNA License"); and the Non-Exclusive License Agreement between Roche and City of Hope dated September 19, 2011 (collectively the "RNAi Licenses").
- Abbreviated New Drug Applications for Generic Drugs In 1984, with passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the "Hatch-Waxman Amendments") amending the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 282.85 | ▼ 2.87% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 73.28 | ▼ 0.06% |
| AXSM | Axsome Therapeutics, Inc. | USD 255.17 | ▲ 3.58% |
| ACAD | ACADIA Pharmaceuticals Inc. | USD 21.09 | ▼ 0.75% |
| SRPT | Sarepta Therapeutics, Inc. | USD 15.31 | ▲ 1.32% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 13, 2026 at 11:45 UTC. This page is informational and not investment advice.